Assay that Combines Clinical, Radiomic Characteristics with CT Information Shown to Better Distinguish Malignant Early Lung Nodules

Comprehensive Analysis of Proteomics Identifies New, Druggable Drivers of NSCLC—and New Avenue for Continued Research

Atezolizumab Approved for Adjuvant NSCLC Therapy for Patients with Stage II-IIIA Disease, PD-L1 ≥ 1%

Toward More Inclusive, Accessible Clinical Trial Consent Forms

Spine Stereotactic Radiosurgery: A Critical Evaluation of the Evidence to Guide Clinical Practice

Treatment of Immunotherapy-Related Ophthalmic Toxicities: An Interview With Dr. Asim V. Farooq

Ticiana Leal, MD, Moves to Emory University School of Medicine

Balancing the Benefits and Harms of Lung Cancer Screening

The eNRGy1 Global Multicenter Registry: NRG1 Fusions as a Hidden Target in Lung Cancer

Adoption of VATS Continues to Vary Globally

First New Second-line Therapy for SCLC in Australia in 20 Years

Sotorasib Scores Second-line Approval in Canada